New antibody shot could shield women from malaria

NCT ID NCT07060508

Recruiting now Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 08, 2026 · Updated 15 times

Summary

This study tests whether a single dose of L9LS, a lab-made antibody, can safely prevent malaria in women of childbearing potential in Mali. About 290 healthy women and men will receive either the antibody or a placebo and be monitored for 24 weeks. The goal is to see if the antibody blocks malaria infection without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Faladje MRTC Clinic
RECRUITING

Faladié, Koulikoro, Mali

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kalifabougou MRTC Clinic
RECRUITING

Kalifabougou, Koulikoro, Mali

Contact Phone: •••-•••-•••• Email: •••••@•••••
Torodo MRTC Clinic
RECRUITING

Torodo, Koulikoro, Mali

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MALARIA MALARIA